Latest SEC filings for Recursion Pharmaceuticals, Inc. (RXRX) explained in plain English: insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). Sourced directly from SEC EDGAR.
Gibson Christopher, listed as Director at RECURSION PHARMACEUTICALS, INC., reported an open-market sale of 40,000 RXRX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Gibson Christopher filed a Form 144 with the SEC indicating intent to sell RXRX (RECURSION PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Taylor Ben R (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Gibson Christopher, listed as Director at RECURSION PHARMACEUTICALS, INC., reported an open-market sale of 40,000 RXRX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Borgeson Blake, listed as Director at RECURSION PHARMACEUTICALS, INC., reported an open-market sale of 30,000 RXRX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Gibson Christopher filed a Form 144 with the SEC indicating intent to sell RXRX (RECURSION PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Borgeson Blake filed a Form 144 with the SEC indicating intent to sell RXRX (RECURSION PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Dar Zavain (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Li Dean Y (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
RECURSION PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Gibson Christopher, listed as Director at RECURSION PHARMACEUTICALS, INC., reported an open-market sale of 40,000 RXRX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Gibson Christopher filed a Form 144 with the SEC indicating intent to sell RXRX (RECURSION PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Taylor Ben R, listed as Chief Financial Officer at RECURSION PHARMACEUTICALS, INC., reported an open-market sale of 7,956 RXRX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Taylor Ben R filed a Form 144 with the SEC indicating intent to sell RXRX (RECURSION PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Gibson Christopher (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.